OakChart

Instil Bio Inc

TILHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:05 PM ET

6.350.00 (0.00%)
2026-11-11 21:14 CET
Market cap
43.07 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-30.28 USD m
Free cash flow, TTM
-23.61 USD m
EPS diluted, TTM
-4.47
P/E
-
Compare

Price

TIL against its 20, 50 and 200-day averages
2050200miss
6.008.0010.0012.0014.0075K150KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TILclose 6.3520-day 6.3150-day 6.79200-day 7.666.3552w low

60.3% under the 52-week high of 16.00 on 11 Nov 2025. 52-week low 5.56 on 27 Oct 2026. Last 15 sessions, 28.1% high to low

Volume 1.58× normal · the line is the 50-bar volume average

Profile

TIL
52-week range, 8% of the way up
5.5616.00

Instil Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company was founded in August 2018 and is headquartered in Dallas, TX.

Employees17
IPOMar 19, 2021
Beta1.96
ATR, 14d0.43
Rel volume1.58
Short float4.35%
Insider own38.58%
Inst own28.33%

Snapshot

6 groups

Valuation

Index-
Market Cap43.07M
Enterprise Value60.56M
Income-30.28M
Sales0.00M
Book/sh15.83
Cash/sh10.31
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees17
IPOMar 19, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.40
P/C0.62
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio21.67
Current Ratio21.67
Debt/Eq0.81
LT Debt/Eq0.81
Option/ShortNo / Yes

Earnings

EPS (ttm)-4.47
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y32.28% -12.70%
Sales past 3/5Y- -
EPS Y/Y TTM65.39%
Sales Y/Y TTM-
EPS Q/Q80.45%
Sales Q/Q-
EarningsAug 13 AMC
EPS/Sales Surpr.-80.00% -

Ownership

Insider Own38.58%
Insider Trans0.00%
Inst Own28.33%
Inst Trans0.30%
ROA-14.13%
ROE-25.33%
ROIC-15.58%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA200.71%
SMA50-6.52%
SMA200-17.15%
Trades-

Technical

Shs Outstand6.78M
Shs Float4.17M
Short Float4.35%
Short Ratio5.89
Short Interest0.18M
52W High16.00 -60.31%
52W Low5.56 14.21%
Volatility8.50% 7.68%
ATR (14)0.43
RSI (14)45.74
Beta1.96
Rel Volume1.58
Avg Volume30.78K
Volume43,012

Performance

Perf Week-9.16%
Perf Month2.75%
Perf Quarter-12.65%
Perf Half Y-20.82%
Perf YTD-42.27%
Perf Year-59.68%
Perf 3Y-9.29%
Perf 5Y-98.57%
Perf 10Y-
Recom3.00
Target Price7.00
Prev Close6.35
Price6.35
Change %0.00%

Analyst ratings

latest 10 of 11
DateActionAnalystRating changeTargetImplied
Jan 07, 2026DowngradeHH.C. WainwrightBuy → Neutral
Jan 06, 2026DowngradeRRobert W. BairdOutperform → Neutral$7+10.2%
Jan 07, 2025UpgradeJJefferiesHold → Buy$11 → $52+718.9%
Nov 04, 2024InitiatedJJMP SecuritiesMkt Perform
Apr 12, 2024DowngradeJJefferiesBuy → Hold$5 → $11+73.2%
Nov 01, 2022DowngradeTTruistBuy → Hold$16 → $6-5.5%
Nov 01, 2022DowngradeCCowenOutperform → Market Perform
Aug 13, 2021InitiatedRRobert W. BairdOutperform$34+435.4%
Apr 13, 2021InitiatedTTruistBuy$32+403.9%
Apr 13, 2021InitiatedMMorgan StanleyEqual-Weight$24+278.0%

Peers

Mkt cap
TickerCompanyMkt cap
CBIOCrescent Biopharma Inc539.14M
CMPXCompass Therapeutics Inc149.54M
SMMTSummit Therapeutics Inc13.37B
ALXOAlx Oncology Holdings Inc156.95M
ELTXElicio Therapeutics Inc45.29M
HOWLWerewolf Therapeutics Inc47.15M
IOVAIovance Biotherapeutics Inc3.71B
LYELLyell Immunopharma Inc412.30M
PMVPPMV Pharmaceuticals Inc94.77M
BNTXBioNTech SE ADR21.62B

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
DFACU.S. Core Equity 2 Portfolio-ETF Class SharesAUM: 49.14B
DCORUS Core Equity 1 Portfolio ETF Class SharesAUM: 3.65B
DFSUDimensional US Sustainability Core 1 ETFAUM: 2.38B

News

latest 14 of 198
  • Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
  • Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
  • Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -6.82%
  • Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco (GlobeNewswire) -45.81%
  • Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -7.20%
  • Instil Bio Announces ImmuneOnco's Presentation of '2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC) (GlobeNewswire) -9.81%
  • Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
  • ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China (GlobeNewswire) -11.14%
  • Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors (GlobeNewswire) +8.57%
  • Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know (Zacks)
  • Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet (Zacks)
  • Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program (GlobeNewswire)
  • Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice (Zacks) +15.05%
  • Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results (Zacks) +10.02%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-0.630-0.350-0.6300.00-1
2026Q12026-05-15-0.620-0.590-0.6200.00-2
2025Q42026-03-27-1.210-2.038-1.2080.000.004
2025Q32025-11-13-2.010-2.355-2.0110.000.004
2025Q22025-08-13-3.240-2.503-3.2430.000.004
2025Q12025-05-13-4.320-2.588-4.3170.000.004
2024Q42025-03-04-1.820-3.220-1.8230.000.004
2024Q32024-11-13-3.540-2.108-3.5380.001.904
2024Q22024-08-13-2.290-2.980-2.2940.00-2
2024Q12024-05-10-2.390-2.230-3.7370.00-2
2023Q42024-03-21-1.260-2.845-1.987--2
2023Q32023-11-13-10.370-2.000-10.368--4
2023Q22023-08-11-2.800-2.950-2.869--4
2023Q12023-05-11-8.800-3.100-8.7740.00-2
2022Q42023-03-31-7.200-8.266-8.2920.001.003
2022Q32022-11-14-7.400-8.720-8.6710.000.005

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-37.900--5.8870.09-
2021FY-29.600-25.050-24.3040.000.05
2022FY-29.600-33.133-34.4640.000.50
2023FY-10.140-24.850-23.9990.00-
2024FY-11.390-12.723-11.3880.000.00
2025FY-10.700-11.530-10.7000.000.00
2026FY--1.170---
2027FY--8.280--0.00
2028FY--11.060--8.44

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2025-11-131000.000.000.00
2026Q3S2025-11-111000.000.000.00
2026Q3S2025-11-101000.000.000.00
2026Q3S2025-11-091000.000.000.00
2026Q3S2025-11-081000.000.000.00
2026Q3S2025-11-071000.000.000.00
2026Q3S2025-11-061000.000.000.00
2026Q3S2025-11-051000.000.000.00
2026Q3S2025-11-041000.000.000.00
2026Q3S2025-11-031000.000.000.00
2026Q3S2025-11-021000.000.000.00
2026Q3S2025-11-011000.000.000.00
2026Q3S2025-10-311000.000.000.00
2026Q3S2025-10-301000.000.000.00

Estimate history

EPS, annual-1.017-5.887-24.304-34.464-23.999-11.388-10.703-4.4721
Period2019202020212022202320242025TTM
EPS, quarterly-2.294-3.538-1.823-4.317-3.243-2.011-1.208-0.62-0.634
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00.138000000
Period2019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual6.4116.4116.4516.5046.5046.5266.7826.782
Period2019202020212022202320242025MRQ
Shares, quarterly6.5046.5256.5266.5596.7516.7826.7826.7826.782
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.000.000.140.00
Cost of Goods Sold Incl. D&A0.280.533.614.765.992.750.260.02
Gross Profit-0.28-0.53-3.61-4.76-5.99-2.75-0.12-0.02
Selling, General and Administrative Excl. Other35.7152.3756.3585.78200.18152.5133.536.57
Research and Development13.5625.6915.7542.99143.94106.9619.404.03
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-36.00-52.91-59.96-90.54-206.17-155.27-33.64-6.58
Interest Expense6.285.838.995.211.880.000.000.00
Unusual Expense-0.4525.6713.5868.6320.290.290.000.00
Net Income Before Taxes-30.28-71.37-74.14-156.09-225.25-156.75-37.59-6.52
Income Taxes0.000.000.000.00-2.070.040.150.00
Consolidated Net Income-30.28-71.37-74.14-156.09-223.18-156.79-37.74-6.52
Net Income From Continuing Operations-30.28-71.37-74.14-156.09-223.18-156.79-37.74-6.52
Net Income-30.28-71.37-74.14-156.09-223.18-156.79-37.74-6.52
EPS (Recurring)-4.51-8.01-9.93-16.61-32.27-24.27-5.89-1.02
EPS (Basic, Before Extraordinaries)-4.47-10.70-11.39-24.00-34.46-24.30-5.89-1.02
EPS (Diluted)-4.47-10.70-11.39-24.00-34.46-24.30-5.89-1.02
EBITDA-35.71-52.37-56.35-85.78-200.18-152.51-33.39-6.57
Non-Operating Income (Expense)11.5513.048.408.293.09-1.20-3.940.06
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.398.6917.2618.1724.0519.121.250.29
Gross Margin-------85.51-
Operating Margin-------24,379.71-
Net Margin-------27,346.38-
Shares Outstanding6.786.786.536.506.506.456.416.41
Market Capitalization43.0743.07124.5849.5681.742,207.672,160.94-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.250.010.010.010.010.500.740.90
Gross Profit-0.25-0.01-0.01-0.01-0.01-0.50-0.74-0.90
Selling, General and Administrative Excl. Other5.156.019.5415.0112.8913.9810.7310.37
Research and Development0.270.673.509.136.745.371.100.56
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-5.40-6.02-9.56-15.02-12.90-14.48-11.47-11.27
Interest Expense1.581.551.571.581.581.102.592.01
Unusual Expense0.18-0.630.000.0010.5416.080.7612.36
Net Income Before Taxes-4.30-4.20-8.19-13.59-21.39-28.20-11.89-23.02
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-4.30-4.20-8.19-13.59-21.39-28.20-11.89-23.02
Net Income From Continuing Operations-4.30-4.20-8.19-13.59-21.39-28.20-11.89-23.02
Net Income-4.30-4.20-8.19-13.59-21.39-28.20-11.89-23.02
EPS (Recurring)-0.62-0.68-1.21-2.01-2.12-2.59-1.74-2.21
EPS (Basic, Before Extraordinaries)-0.63-0.62-1.21-2.01-3.24-4.32-1.82-3.54
EPS (Diluted)-0.63-0.62-1.21-2.01-3.24-4.32-1.82-3.54
EBITDA-5.15-6.01-9.54-15.01-12.89-13.98-10.73-10.37
Non-Operating Income (Expense)2.862.742.933.023.633.462.932.62
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.040.981.611.771.823.504.504.07
Shares Outstanding6.786.786.786.786.756.566.536.53
Market Capitalization43.0755.8874.60120.57136.64113.29124.58437.84

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments76.30115.14151.86260.92454.10241.718.89
Short Term Receivables0.852.620.000.000.000.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets114.296.708.908.469.924.420.39
Total Current Assets191.43124.47160.76269.38464.02246.149.29
Net Property, Plant & Equipment0.36130.34141.07209.34122.0055.340.19
Total Investments and Advances0.000.0023.160.000.500.050.00
Long-Term Note Receivable7.66------
Intangible Assets---0.0015.8315.830.00
Deferred Tax Assets2.141.19-----
Other Assets4.078.760.643.417.641.660.00
Total Assets205.66264.76325.63482.13609.98319.019.48
Short Term Debt Incl. Current Port. of LT Debt0.371.681.752.380.000.000.00
Accounts Payable0.780.661.212.365.573.500.98
Other Current Liabilities3.695.557.6028.0535.799.790.44
Total Current Liabilities4.847.9010.5632.7941.3613.281.42
Long Term Debt84.8185.2084.3077.520.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities2.141.19--2.432.47-
Other Liabilities0.011.034.948.2111.0010.890.00
Total Liabilities91.8095.3299.80118.5254.7826.641.42
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00331.9714.95
Common Equity113.87169.44225.83363.61555.20-39.60-6.89
Total Shareholders Equity113.87169.44225.83363.61555.20292.378.06
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity113.87169.44225.83363.61555.20292.378.06
Total Liabilities & Stockholders Equity205.66264.76325.63482.13609.98319.019.48
Book Value Per Share16.7925.9634.7255.9186.06-6.18-1.08
Tangible Book Value Per Share16.7925.9634.7255.9183.61-8.65-1.08
Full-Time Employees171449192412150-
Price to Book Ratio0.400.710.210.203.983.59-
Return on Assets-30.34-25.11-38.65-40.87-33.76-22.98-
Return on Equity-50.39-37.51-52.96-48.58-37.00-25.12-
Return on Invested Capital-35.92-29.11-50.33-50.59-28.24-12.91-80.96
Quick Ratio39.5315.7615.228.2211.2218.536.54
Current Ratio39.5315.7615.228.2211.2218.536.54

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-30.28-71.37-74.14-156.09-223.18-156.79-37.74-6.52
Depreciation0.280.533.614.767.752.750.260.02
Other Funds (Non Cash)6.3134.7827.4378.3244.8327.546.390.84
Funds from Operations-23.68-36.06-43.09-73.01-170.60-126.50-31.09-5.66
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital0.07-0.56-12.61-9.02-9.574.361.480.37
Cash from Operating Activities-23.61-36.62-55.70-82.03-180.16-122.14-29.62-5.29
Capital Expenditures-10.00-10.00-10.00-20.66-84.59-57.83-50.82-0.21
Net Assets From Acquisitions0.000.000.000.000.000.00-0.310.00
Sale of Fixed Assets and Businesses0.010.430.870.000.000.000.000.00
Purchase or Sale of Investments31.2335.0464.0960.23200.30-416.560.000.00
Purchase of Investments-63.77-100.86-134.01-301.47-665.05-1,107.570.000.00
Sale Or Maturity of Investments95.00135.90198.10361.70865.35691.000.000.00
Other Uses0.000.00-1.590.00-1.170.000.00-0.55
Other Sources0.000.000.601.560.000.000.000.00
Cash from Investing Activities21.2425.4853.9741.13114.54-474.40-51.12-0.76
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock-6.230.850.360.001.55393.23312.9814.95
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock-6.230.850.360.001.55393.23312.9814.95
Proceedsfrom Stock Options-6.610.000.000.000.00391.48312.6214.95
Issuance or Reduction of Debt, Net6.616.612.768.0870.340.000.000.00
Change in Long Term Debt6.616.612.768.0870.340.000.000.00
Issuance of Long Term Debt6.616.6185.608.6770.340.000.000.00
Reduction of Long Term Debt0.000.00-82.84-0.590.000.000.000.00
Net Financing Active Other Cash Flow0.00-0.17-1.370.000.00-0.070.070.00
Other Financing Activities Uses0.00-0.17-1.370.000.00-0.070.000.00
Cash from Financing Activities0.387.291.758.0871.89393.16313.0514.95
Exchange Rate Effect-0.050.02-0.09-0.20-0.64-0.300.560.00
Net Change in Cash-2.04-3.83-0.06-33.025.63-203.67232.878.89
Free Cash Flow-23.61-36.62-55.70-102.69-264.75-179.97-80.43-5.50
Preferred Dividends (Cash Flow)-0.000.000.000.000.00--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments69.9374.6976.3079.9591.97104.61
Short Term Receivables0.030.030.850.840.810.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.65113.58114.29115.47114.61114.65
Total Current Assets71.61188.30191.43196.26207.39219.26
Net Property, Plant & Equipment113.930.170.360.550.740.93
Total Investments and Advances0.000.000.003.4411.667.19
Deferred Tax Assets--2.14---
Other Assets3.913.994.074.1511.2010.07
Total Assets197.71200.43205.66211.77230.99237.45
Short Term Debt Incl. Current Port. of LT Debt0.390.190.370.300.462.39
Accounts Payable0.800.790.780.930.520.29
Other Current Liabilities2.123.743.694.4612.874.55
Total Current Liabilities3.314.724.845.7013.857.23
Long Term Debt87.0385.0084.8184.6184.4384.28
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--2.14---
Other Liabilities0.000.010.011.041.041.03
Total Liabilities90.3389.7391.8091.3599.3292.54
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity107.38110.70113.87120.42131.67144.91
Total Shareholders Equity107.38110.70113.87120.42131.67144.91
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity107.38110.70113.87120.42131.67144.91
Total Liabilities & Stockholders Equity197.71200.43205.66211.77230.99237.45
Book Value Per Share15.8316.3216.7917.7619.5022.09
Tangible Book Value Per Share15.8316.3216.7917.7619.5022.09
Full-Time Employees--17---
Price to Book Ratio0.400.490.620.920.940.67
Return on Assets-14.13-21.64-30.34-31.00-32.18-28.70
Return on Equity-25.33-37.07-50.39-50.60-51.74-44.50
Return on Invested Capital-2.21-2.15-4.12-6.63-9.90-12.30
Quick Ratio21.6739.8739.5334.4514.9730.33
Current Ratio21.6739.8739.5334.4514.9730.33

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-4.30-4.20-8.19-13.59-21.39-28.20
Depreciation0.250.010.010.010.010.50
Other Funds (Non Cash)1.501.560.972.2811.6419.89
Funds from Operations-2.55-2.63-7.20-11.30-9.74-7.81
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-2.091.300.130.74-5.053.62
Cash from Operating Activities-4.64-1.34-7.08-10.56-14.79-4.20
Capital Expenditures0.000.00-10.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.010.010.010.41
Purchase or Sale of Investments5.29-0.327.8118.44-0.419.21
Purchase of Investments-17.51-22.32-17.39-6.56-38.71-38.19
Sale Or Maturity of Investments22.8022.0025.2025.0038.3047.40
Other Uses0.000.0010.00-10.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities5.29-0.327.828.45-0.409.61
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.00-6.610.386.680.40
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.00-6.610.386.680.40
Proceedsfrom Stock Options0.000.00-6.610.006.610.00
Issuance or Reduction of Debt, Net0.000.006.610.000.000.00
Change in Long Term Debt0.000.006.610.000.000.00
Issuance of Long Term Debt0.000.006.610.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.00-0.17
Other Financing Activities Uses0.000.000.000.000.00-0.17
Cash from Financing Activities0.000.000.000.386.680.23
Exchange Rate Effect0.00-0.01-0.02-0.030.020.04
Net Change in Cash0.65-1.660.72-1.76-8.495.69
Free Cash Flow-4.64-1.34-7.08-10.56-14.79-4.20

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.35%0.2M4.2M25.67K
2026-10-154.09%0.2M4.2M13.78K
2026-09-303.81%0.2M4.2M11.60K
2026-09-153.88%0.2M4.2M12.25K
2026-08-313.76%0.2M4.2M12.41K
2026-08-144.23%0.2M4.2M17.62K
2026-07-314.64%0.2M4.1M21.08K
2026-07-155.05%0.2M4.0M21.97K
2026-06-305.81%0.2M4.0M25.71K
2026-06-155.79%0.2M4.0M25.90K
2026-05-295.76%0.2M4.0M28.60K
2026-05-155.73%0.2M4.0M32.87K
2026-04-306.48%0.3M4.0M38.60K
2026-04-158.19%0.3M4.0M48.50K
2026-03-3110.35%0.4M4.0M118.13K
2026-03-139.95%0.4M4.0M124.60K
2026-02-2710.39%0.4M4.0M127.97K
2026-02-1310.43%0.4M4.0M131.25K
2026-01-3011.54%0.5M4.0M130.72K
2026-01-1512.23%0.5M4.0M127.60K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-118-KCurrent report2026-06-11SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-158-KCurrent report2026-05-15SEC
2026-04-24ARSAnnual report to security holders. 2025-12-31SEC
2026-04-24DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-24DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-11SEC
2026-04-038-KCurrent report2026-04-01SEC
2026-03-2710-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-278-KCurrent report2026-03-27SEC
2026-03-27S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-02-09SCHEDULE 13G/ASEC
2026-01-068-KCurrent report2026-01-05SEC
2025-11-1310-QQuarterly report pursuant to Section 13 or 15(d)2025-09-30SEC
2025-11-138-KCurrent report2025-11-13SEC
2025-09-124Statement of changes in beneficial ownership of securities2025-09-10SEC
2025-09-10144Filing for proposed sale of securities under Rule 144.SEC
2025-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2025-06-30SEC
2025-08-138-KCurrent report2025-08-13SEC
2025-08-12SCHEDULE 13G/ASEC
2025-07-318-KCurrent report2025-07-31SEC
2025-05-294Statement of changes in beneficial ownership of securities2025-05-28SEC
2025-05-294Statement of changes in beneficial ownership of securities2025-05-28SEC
2025-05-294Statement of changes in beneficial ownership of securities2025-05-28SEC
2025-05-294Statement of changes in beneficial ownership of securities2025-05-28SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Curative Ventures V LLC28.00%
BML Capital Management, LLC9.52%
Vivo Capital, LLC4.32%
UBS Group AG3.39%
Kalehua Capital Management LLC2.94%
VANGUARD CAPITAL MANAGEMENT LLC2.41%
MILLENNIUM MANAGEMENT LLC1.98%
BlackRock, Inc.0.82%
RENAISSANCE TECHNOLOGIES LLC0.74%
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.0.74%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.75%
Nomura Healthcare Fund0.74%
VANGUARD EXTENDED MARKET INDEX FUND0.61%
Fidelity Extended Market Index Fund0.27%
iShares Micro-Cap ETF0.19%
T. Rowe Price Extended Equity Market Index Fund0.13%
Avantis U.S. Small Cap Equity ETF0.11%
Fidelity Total Market Index Fund0.10%
Dimensional U.S. Small Cap ETF0.10%
Fidelity Series Total Market Index Fund0.08%

OakChart. TIL. Cached 15 minutes.

Some panels did not load: insider.